EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.
作者： D Irmer , J O Funk , A Blaukat
关键词:
摘要: … mice expressing mutant EGFR were applied to study the impact of these genetic alterations on cellular signaling and cell fate. This review … of EGFR kinase domain mutations for EGFR-…
nature.com
sci-hub.se 
researchgate.net 参考文章(83)
H Mellstedt, Monoclonal antibodies in human cancer. Drugs of Today. ,vol. 39, pp. 1- 16 ,(2003)
Y Yarden, The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. European Journal of Cancer. ,vol. 37, pp. 3- 8 ,(2001) , 10.1016/S0959-8049(01)00230-1
L. Paz-Ares, J. M. Sanchez, A. García-Velasco, B. Massuti, G. López-Vivanco, M. Provencio, A. Montes, D. Isla, M. L. Amador, R. Rosell, A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) Journal of Clinical Oncology. ,vol. 24, pp. 7020- 7020 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.7020
G. H. Sato, J. Mendelsohn, J. Polikoff, J. D. Sato, A. D. Le, T. Kawamoto, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Molecular biology & medicine. ,vol. 1, pp. 511- 529 ,(1983)
Assessing EGFR mutations. The New England Journal of Medicine. ,vol. 354, pp. 526- ,(2006) , 10.1056/NEJMC052564
Shinichi Toyooka, Katsuyuki Kiura, Tetsuya Mitsudomi, None, EGFR mutation and response of lung cancer to gefitinib. The New England Journal of Medicine. ,vol. 352, pp. 2136- ,(2005) , 10.1056/NEJM200505193522019
Marina Holgado-Madruga, David K. Moscatello, Jaclyn A. Biegel, George Gunn, Roberta L. Hayes, Albert J. Wong, Gloria Ramirez, Philip W. Zoltick, Andrew K. Godwin, Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors Cancer Research. ,vol. 55, pp. 5536- 5539 ,(1995)
John D. Minna, Adi Gazdar, Joyce E. Ohm, Denise Juroske, Jonathan R. Pollack, Michael Peyton, Kiyoshi Yanagisawa, Yuhui Huang, Joseph Amann, J. Stuart Salmon, Hisayuki Shigematsu, David P. Carbone, Pierre P. Massion, Shailaja Kalyankrishna, Young H. Kim, Jonathan M. Kurie, Luc Girard, Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer Cancer Research. ,vol. 65, pp. 226- 235 ,(2005)
M.W. Pedersen, M. Meltorn, L. Damstrup, H.S. Poulsen, The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy Annals of Oncology. ,vol. 12, pp. 745- 760 ,(2001) , 10.1023/A:1011177318162
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736